Moses M. Kasembeli - Concepedia

Author

Moses M. Kasembeli

Also Known As

M M Kasembeli, Moses Kasembeli, Moses M Kasembeli, Moses M. Kasembeli, Moses Makokha Kasembeli, Moses, M. Kasembeli, Moses M. Kasembeli

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Baylor College of Medicine The University of Texas MD Anderson Cancer Center Children's Cancer Center Rice University Houston Methodist

About

Moses M. Kasembeli is an author at Baylor College of Medicine specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	492
2	Cell Biology	6	6	279
3	Natural Sciences	3	3	47
4	Chemical Biology	2	2	32
5	Health Sciences	1	1	41

Moses M. Kasembeli

Publications

Citations

H-Index

Page 1

	Year	Citations
Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer Uddalak Bharadwaj, T. Kris Eckols, Mikhail Kolosov, Oncogene Direct Stat3 InhibitorMedicineBreast CancerPharmacotherapyIdentified Piperlongumine	2014	153
Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation Xuejun Xu, Moses M. Kasembeli, Xueqing Jiang, PLoS ONE	2009	129
Modulation of STAT3 Folding and Function by TRiC/CCT Chaperonin Moses M. Kasembeli, Wilson Chun Yu Lau, Soung‐Hun Roh, PLoS Biology	2014	114
Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma Uddalak Bharadwaj, T. Kris Eckols, Xuejun Xu, Oncotarget Cancer BiologyTreatment ResistanceTumor BiologySignaling PathwaySmall-molecule Inhibition	2016	111
Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance Prema Robinson, Moses M. Kasembeli, Uddalak Bharadwaj, BioMed Research International Breast OncologyApoptosisImmunologySp Receptor AntagonistCell Death	2016	65
PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2 Nan Li, Lin Feng, Hui Liu, Cell Reports	2016	63
Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer Katherine Lewis, Uddalak Bharadwaj, T. Kris Eckols, Lung Cancer Cancer ResearchSignaling PathwayMedicineSignal TransducerBronchial Neoplasm	2015	59
Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis Sebastian Wurster, Nathaniel D. Albert, Uddalak Bharadwaj, Frontiers in Immunology	2022	56
TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain Moses M. Kasembeli, Pooja Singhmar, Jiacheng Ma, Biochemical Pharmacology Pain MedicineNeuropathic PainMolecular PainTumor BiologyInflammation	2021	41
Rhodium(II) Proximity‐Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti‐Leukemia Activity Matthew B. Minus, Wei Liu, Farrukh Vohidov, Angewandte Chemie International Edition	2015	37

Page 1